Brind.
  1. PTC Therapeutics seeks FDA approval for Sephience™, backed by positive Phase 2 results in Huntington's Disease, and plans a global launch in Europe.

FDA approved Sephience for PKU treatment, with ongoing review applications in Japan and Brazil.

2 reports, 1 independent Updated Jul 29
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA approved Sephience for PKU treatment, with ongoing review applications in Japan and Brazil.

Who's involved

What this event is mainly about
FDAPTC Therapeutics

Keep exploring

Part of

PTC Therapeutics seeks FDA approval for Sephience™, backed by positive Phase 2 results in Huntington's Disease, and plans a global launch in Europe. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswirePTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Broad labeling inclusive of all disease subtypes for i
  • Unknown outlet